panitumumab,bevacizumab
amgen,takeda,roche
['paradigm']
important question on paradigm data: why a targeted therapy struggles to prove superiority against bev? we need to understand biology since it seems that egfr pathway inhibition is significant only in a minority of raswt pts. #asco22
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.